沙库巴曲缬沙坦对射血分数中间值心力衰竭患者临床疗效与N末端B型钠尿肽前体及心室重塑的影响
Effect of Sackubatrol Valsartan on Clinical Efficacy,N-terminal B-type Natriuretic Peptide Precursor and Ventricular Remodeling in Patients with Heart Failure with Median Ejection Fraction
程倩1
作者信息
- 1. 北京市健宫医院心内科,北京 100045
- 折叠
摘要
目的 探讨沙库巴曲缬沙坦对射血分数中间值心力衰竭(HFmrEF)患者临床疗效、N 末端 B 型钠尿肽前体(NT-proBNP)及心室重塑的影响.方法 选取 2021 年 9 月至 2022 年 9 月北京市健宫医院收治的 196 例HFmrEF患者作为研究对象,按随机数字表法分为观察组(n=98)与对照组(n=98).对照组给予常规治疗,观察组给予沙库巴曲缬沙坦治疗,比较两组临床疗效、NT-proBNP、心室重塑及不良反应.结果 观察组(95.92%)治疗有效率较对照组(87.76%)更高(P＜0.05);治疗后两组 NT-proBNP 水平降低(P＜0.05),且观察组低于对照组(P＜0.05);治疗后两组左心室心肌质量指数(LVMI)、左室重构指数(LVRI)、室间隔厚度(IVST)、左心室后壁厚度(LVPWT)降低(P＜0.05),且观察组低于对照组(P＜0.05);观察组(5.10%)不良反应发生率较对照组(14.29%)更低(P＜0.05).结论 沙库巴曲缬沙坦应用于HFmrEF患者治疗中,能提高临床疗效,逆转心室重塑,改善NT-proBNP水平,降低不良反应发生率.
Abstract
Objective To explore the effects of sackubatrol valsartan on clinical efficacy,N-terminal B-type natriuretic peptide precursor(NT-proBNP)and ventricular remodeling in patients with intermediate ejection fraction heart failure(HFmrEF).Methods A total of 196 HFmrEF patients admitted to Beijing Jiangong Hospital from September 2021 to September 2022 were selected as the study objects,and were divided into observation group(n=98)and control group(n=98)according to random number table method.The control group was given conventional treatment,and the observation group was given sackubatrol valsartan treatment.The clinical efficacy,NT-proBNP,ventricular remodeling and adverse reactions of the two groups were compared.Results The effective rate of observation group(95.92%)was higher than that of control group(87.76%)(P＜0.05).After treatment,the level of NT-proBNP in the two groups was decreased(P＜0.05),and the observation group was lower than the control group(P＜0.05).After treatment,left ventricular mass index(LVMI),left ventricular remodeling index(LVRI),interventricular septal thickness(IVST)and left ventricular posterior wall thickness(LVPWT)were decreased in both groups(P＜0.05),and the observation group was lower than the control group(P＜0.05).The incidence of adverse reactions in observation group(5.10%)was lower than that in control group(14.29%)(P＜0.05).Conclusion The application of sackubatrol valsartan in the treatment of HFmrEF patients can improve clinical efficacy,reverse ventricular remodeling,improve the level of NT-proBNP,and reduce the incidence of adverse reactions.
关键词
沙库巴曲缬沙坦/射血分数中间值心力衰竭/N末端B型钠尿肽前体/心室重塑Key words
Sackubatrol valsartan/Heart failure with median ejection fraction/N-terminal B-type natriuretic peptide precursor/Ventricular remodeling引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据